Clinical Trial Update: An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees [Phase 2]

View source ↗

Summary

Phase II open-label study assessing immunogenicity and safety of a single IMVAMUNE booster given two years after prior vaccination in former participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• IMVAMUNE (Modified Vaccinia Ankara (MVA))

Snippet

Sponsor: Bavarian Nordic | Conditions: Smallpox | Phase 2 | Status: COMPLETED | Results posted: 2019-02-18